Signaling by MAP2K mutants
Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014 Dec;13(12):928–42. doi: 10.1038/nrd4281. PMID: 25435214.; Bezniakow N, Gos M, Obersztyn E. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes. Dev Period Med. 2014 Jul;18(3):285–96. PMID: 25182392.; Rauen KA. The RASopathies. Annu. Rev. Genom. Hum. Genet. 2013 Aug 31;14(1):355–69. doi: 10.1146/annurev-genom-091212-153523.
Metabolites
Enzyme
| EC Number | name | full name | note |
|---|---|---|---|
| 2.7.12.2 | mitogen-activated protein kinase kinase | ATP:protein phosphotransferase (MAPKKK-activated) |
Proteins
| Protein ID | name | full name |
|---|